BioCentury | Dec 23, 2020
Product Development
Dec. 21-23 Quick Takes: readouts for Genentech, Rhythm, ChemoCentryx and BMS
...in a Phase II ACCOLADE trial to treat C3G, a rare kidney disease. However, the C5AR1...
...primary endpoint of progression-free survival in September 2019.TARGETSANG2 (ANGPT2) – Angiopoietin 2C5AR1 (C5AR; CD88) – Complement receptor 5A BC...
...primary endpoint of progression-free survival in September 2019.TARGETSANG2 (ANGPT2) – Angiopoietin 2C5AR1 (C5AR; CD88) – Complement receptor 5A BC...